Nasal Covid booster dose gets approval for phase III trials, more safe, says Bharat Biotech

NEW DELHI: Vaccine manufacturer Bharat Biotech has been granted permission to conduct phase III clinical trials of an intranasal booster dose, on those who have received both doses of Covaxin. The Drug Controller General of India has approved to conduct trials at nine locations in the county.

A nasal vaccine can reduce the chances of infection. It is very effective in blocking the transmission of Covid, said Bharat Biotech. An intranasal booster dose can be administered easily. The most important advantage is that it would not require trained healthcare workers for its administration.

Bharat Biotech had sought approval for phase III trials of nasal vaccines, last month. As per reports, trials will be conducted in 900 people.